Moderna has paused its efforts to build an mRNA manufacturing facility in Kenya while it determines future demand for COVID-19 vaccines on the African continent, the firm said in a statement Thursday. Moderna’s plan was part of efforts to widen access to vaccines that have remained out of reach to large parts of the world. Africa has been trying to reduce the continent’s reliance on the rest of the world for vaccine supplies. Demand for COVID-19 vaccines in Africa has declined since the pandemic and is too little to support...

Moderna on Thursday said it has paused plans to build a vaccine manufacturing site in Kenya after a steep drop in demand for its Covid vaccines. The biotech company said it has not received any vaccine orders for Africa since 2022 and has taken more than $1 billion in losses and write-downs related to the cancellation of previous orders from the continent. Moderna's decision aligns with its broader effort to cut costs by resizing its Covid vaccine manufacturing footprint. The company's business took a major hit last year as demand...